In 2007, Zhao et al.[109] demonstrated that deletion of β-catenin might lead to a reduced ability of BCR-ABL, therefore impairing the renewal of normal and CML CSCs in mice. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.